Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Lisinopril Market Expected to Grow Between 2025 And 2029?

In recent times, the lisinopril market has witnessed significant growth. The market value, which is projected to be $1.76 billion in 2024, is expected to increase to $1.88 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.7%. This upward trend in the historical era can be attributed to factors such as enhanced accessibility to the drug, changes in lifestyle, expansion of screening programs, increased availability of generic lisinopril, and improved patient compliance.

What Growth Rate Is Anticipated for the Lisinopril Market in the Coming Years?

The lisinopril market is predicted to experience robust expansion in the forthcoming years, reaching a value of $2.4 billion by 2029 with a compound annual growth rate (CAGR) of 6.3%. This growth during the prediction period can be accredited to the increasing incidences of hypertension, and cardiovascular ailments, the availability of generic substitutes, cost-effectiveness, heightened awareness, early detection, the escalating requirement for efficient treatments, and the aging demographic. Significant trends for the prediction period encompass advancements in medication delivery, the necessity for improved and patient-focused drug delivery tactics, the call for cost-friendly resolutions, the demand for efficacious heart failure treatments, and the need for effective remedies for diabetic kidney diseases.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16465&type=smp

Who Are the Leading Companies in the Lisinopril Market?

Major companies operating in the lisinopril market are Merck & Co. Inc., Pfizer Inc., AbbVie Inc., AstraZeneca Plc, Vitaris Inc., Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc., Hetero Ltd., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd., Cipla Inc., Hikma Pharmaceutical Plc, Apotex Inc., Amneal Pharmaceutical Inc., Lupin Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Metrochem API Private Limited, Calyx Chemicals & Pharmaceuticals Limited, Farmhispania Group, Zydus Cadila Healthcare Ltd., Qingdao Qingmei Biotech Co. Ltd., LGM Pharma LLC, Amara Labs Pvt., Sms Lifesciences

What Are the Key Drivers of the Lisinopril Market?

The expanding incidence of cardiovascular diseases is anticipated to boost the lisinopril market’s growth. Cardiovascular diseases encompass various conditions that interfere with the heart and blood vessels’ functioning. Numerous factors contribute to the rising prevalence of cardiovascular diseases, such as population and aging growth, risk elements, and the failure to enforce tested prevention and treatment methods. Lisinopril plays a pivotal role in managing cardiovascular diseases, chiefly by lowering blood pressure and trimming down strain on the heart and kidneys. It accomplishes this by suppressing angiotensin II production, promoting blood vessel dilation, decreasing blood volume, and shielding organs from damage. As per the Singapore Heart Foundation (SHF), a non-profit organization based in Singapore, there was a minor surge in ischemic heart disease-related deaths from 5,290 in 2022 to 5,302 in May 2024. Hence, the rising incidence of cardiovascular diseases is powering the lisinopril market’s growth. Regarding the Lisinopril Market Driver, the escalating prevalence of hypertension is projected to spur the expansion of the lisinopril market. Commonly referred to as high blood pressure, hypertension is a health condition where the blood’s force against artery walls is persistently excessive. An unhealthy diet, sedentary lifestyle, aging population, and prolonged stress contribute to the growing incidence of hypertension. Lisinopril is an effective treatment for hypertension as it blocks the creation of angiotensin II, which in turn leads to blood vessel relaxation, blood volume reduction, and lower blood pressure. To illustrate this, The World Health Organization, a health organization situated in Switzerland, reported that roughly 1.28 billion individuals aged between 30 and 79 years worldwide had hypertension in March 2023. Thus, the mounting prevalence of hypertension is propelling the lisinopril market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=16465&type=smp

What Are the Key Market Segments in the Lisinopril Industry?

The lisinopril market covered in this report is segmented –

1) By Brand: Zestoretic, Prinivil, Zestril, Other Brands

2) By Disease: Hypertension, Heart Failure, Heart Attack, Strokes, Diabetic Kidney Disease, Other Diseases

3) By Dosage: Tablet, Liquid, Other Dosages

4) By Population Type: Children, Adults

5) By End-Users: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Zestoretic: Different Dosage Forms, Generic Versions Of Zestoretic

2) By Prinivil: Different Dosage Forms, Generic Versions Of Prinivil

3) By Zestril: Different Dosage Forms, Generic Versions Of Zestril

4) By Other Brands: International Brand Variants, Combination Drug Formulations

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/lisinopril-global-market-report

What Are the Key Regional Markets in the Lisinopril Industry?

North America was the largest region in the lisinopril market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lisinopril market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16465

This Report Delivers Insight On:

1. How big is the lisinopril market, and how is it changing globally?

2. Who are the major companies in the lisinopril market, and how are they performing?

3. What are the key opportunities and risks in the lisinopril market right now?

4. Which products or customer segments are growing the most in the lisinopril market?

5. What factors are helping or slowing down the growth of the lisinopril market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model